Novartis, NHS England to collaborate on cardiovascular diseases
The collaboration includes three projects that tackle the CVD challenge and provides enhanced opportunities for life science sector…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Jan 20
The collaboration includes three projects that tackle the CVD challenge and provides enhanced opportunities for life science sector…
13 Jan 20
Fostemsavir was submitted for the US FDA new drug application (NDA), and was granted FDA fast track and…
13 Jan 20
Lilly will expanding its portfolio of Phase 3 medicines with the addition of lebrikizumabfor for atopic dermatitis and…
Asset ManagementActive Pharmaceutical Ingredients and IntermediatesPharmaceuticals
10 Jan 20
AYVAKIT marks the first precision therapy to be approved by the FDA to treat a genomically defined population…
09 Jan 20
FDA has approved KEYTRUDA based on data from KEYNOTE-057, a multicentre, open-label, single-arm trial, involving 96 patients
08 Jan 20
Cerebral Therapeutics develops drug-device combination therapies for patients suffering from severe refractory epilepsy and other neurological diseases
07 Jan 20
BAVENCIO was approved by the US Food and Drug Administration (FDA), for the treatment of patients with locally…
07 Jan 20
In the Phase III DAPA-HF trial, Farxiga has reduced the incidence of the composite outcome of CV death…
Analytics company GlobalData has outlined the four main ways medical robots are being used to improve standards of…
06 Jan 20
DKN-01 is a humanised monoclonal ant- DKK1 antibody that enhances the activity of myeloid-derived suppressor cells and downregulating…